F. Muwalla

发表

DTPACE: A n E ffective, N ovel C ombination C hemotherapy W ith Thalidomide f or P reviously T reated P atients W ith M yeloma

B. Barlogie, N. Munshi, G. Tricot, 2003 .

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

B. Barlogie, E. Anaissie, G. Tricot, 2002, British journal of haematology.

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

B. Barlogie, R. Desikan, E. Anaissie, 2001, British journal of haematology.

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

B. Barlogie, E. Anaissie, G. Tricot, 2002, Bone Marrow Transplantation.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

B. Barlogie, E. Anaissie, G. Tricot, 2003, Experimental hematology.

Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience

B. Barlogie, S. Jagannath, D. Siegel, 2003, British journal of haematology.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

Bart Barlogie, Joth Jacobson, B. Barlogie, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

B. Barlogie, J. Shaughnessy, E. Anaissie, 2003, British journal of haematology.

cells gammopathy of undetermined significance, and normal bone marrow plasma Global gene expression profiling of multiple myeloma, monoclonal

F. Zhan, B. Barlogie, J. Shaughnessy, 2011 .

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

John Crowley, Bart Barlogie, Johanna Hardin, 2002, Blood.

Molecular Profiling of Multiple Myeloma Running Head: Molecular Analysis of Myeloma Section: Neoplasia

F. Zhan, B. Barlogie, J. Shaughnessy, 2001 .

Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

B. Barlogie, D. Siegel, R. Desikan, 2002, British journal of haematology.

Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features

G. Tricot, S. Ward, S. Harik, 2004, Leukemia & lymphoma.

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

B. Barlogie, E. Anaissie, G. Tricot, 2004, Bone Marrow Transplantation.

Severe Neutropenia Following a Prolonged Course of Vancomycin That Progressed to Agranulocytosis with Drug Reexposure

J. Moreb, J. Duff, F. Muwalla, 2012, The Annals of pharmacotherapy.

Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation

Liuyan Jiang, J. Foran, Z. Rahman, 2020, Leukemia research reports.